Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”

on behalf of the GOS Steering Committee

doi:10.3390/jcm12124017

Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”

on behalf of the GOS Steering Committee

Institute for Medical Research Israel-Canada (IMRIC)

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Abstract

Thank you for allowing us the opportunity to respond to the commentary from Mistry and colleagues (Comment: The two substrate reduction therapies for type 1 Gaucher disease are not equivalent) [...].

Original language	English
Article number	4017
Journal	Journal of Clinical Medicine
Volume	12
Issue number	12
DOIs	https://doi.org/10.3390/jcm12124017
State	Published - Jun 2023

Access to Document

10.3390/jcm12124017

Fingerprint

Dive into the research topics of 'Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”'. Together they form a unique fingerprint.

Cite this

on behalf of the GOS Steering Committee (2023). Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”. Journal of Clinical Medicine, 12(12), Article 4017. https://doi.org/10.3390/jcm12124017

on behalf of the GOS Steering Committee. / Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease : Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”. In: Journal of Clinical Medicine. 2023 ; Vol. 12, No. 12.

@article{7bfa8a8866f646928b366441eb890a48,

title = "Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on {\textquotedblleft}Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158{\textquotedblright}",

abstract = "Thank you for allowing us the opportunity to respond to the commentary from Mistry and colleagues (Comment: The two substrate reduction therapies for type 1 Gaucher disease are not equivalent) [...].",

author = "\{on behalf of the GOS Steering Committee\} and Hughes, \{Derralynn A.\} and Patrick Deegan and Pilar Giraldo and {\"O}zlem G{\"o}ker-Alpan and Heather Lau and Elena Lukina and Shoshana Revel-Vilk and Maurizio Scarpa and Jaco Botha and Noga Gadir and Ari Zimran",

year = "2023",

month = jun,

doi = "10.3390/jcm12124017",

language = "אנגלית",

volume = "12",

journal = "Journal of Clinical Medicine",

issn = "2077-0383",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "12",

}

on behalf of the GOS Steering Committee 2023, 'Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”', Journal of Clinical Medicine, vol. 12, no. 12, 4017. https://doi.org/10.3390/jcm12124017

Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”. / on behalf of the GOS Steering Committee.
In: Journal of Clinical Medicine, Vol. 12, No. 12, 4017, 06.2023.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease

T2 - Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”

AU - on behalf of the GOS Steering Committee

AU - Hughes, Derralynn A.

AU - Deegan, Patrick

AU - Giraldo, Pilar

AU - Göker-Alpan, Özlem

AU - Lau, Heather

AU - Lukina, Elena

AU - Revel-Vilk, Shoshana

AU - Scarpa, Maurizio

AU - Botha, Jaco

AU - Gadir, Noga

AU - Zimran, Ari

PY - 2023/6

Y1 - 2023/6

N2 - Thank you for allowing us the opportunity to respond to the commentary from Mistry and colleagues (Comment: The two substrate reduction therapies for type 1 Gaucher disease are not equivalent) [...].

AB - Thank you for allowing us the opportunity to respond to the commentary from Mistry and colleagues (Comment: The two substrate reduction therapies for type 1 Gaucher disease are not equivalent) [...].

UR - https://www.scopus.com/pages/publications/85164194818

U2 - 10.3390/jcm12124017

DO - 10.3390/jcm12124017

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

AN - SCOPUS:85164194818

SN - 2077-0383

VL - 12

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

IS - 12

M1 - 4017

ER -

on behalf of the GOS Steering Committee. Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”. Journal of Clinical Medicine. 2023 Jun;12(12):4017. doi: 10.3390/jcm12124017

Abstract

Access to Document

Other files and links

Fingerprint

Cite this